DeepMed Research

MUNDIPHARMA RESEARCH LIMITED

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR

Phase 3

Terminated

Conditions: Polymyalgia Rheumatica

Interventions: Drug: Prednisone IR (immediate release)
Drug: Lodotra®

First Posted Date: 2013-03-29

Last Posted Date: 2018-10-24

Lead Sponsor: Mundipharma Research Limited

Target Recruit Count: 62

Registration Number: NCT01821040

Locations: 🇬🇧
Southend University Hospital, Westcliff on Sea, United Kingdom

A Study Assessing Patient Handling of Flutiform® Breath-Actuated Inhaler (BAI) and Flutiform® Pressurised Metered Dose Inhaler (pMDI)

Completed

Conditions: Asthma
COPD

Interventions: Device: Flutiform® pMDI and Breath Actuated Inhaler (BAI)

First Posted Date: 2012-12-03

Last Posted Date: 2013-06-28

Lead Sponsor: Mundipharma Research Limited

Target Recruit Count: 332

Registration Number: NCT01739387

Locations: 🇬🇧
BioKinetic Europe Ltd, Belfast, United Kingdom
🇬🇧
Glasgow Clinical Research Facility, Glasgow, United Kingdom

Comparison of Flutiform, Fluticasone and Seretide in Treatment of Moderate to Severe Asthma in Paediatric Patients

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Seretide
Drug: Flixotide
Drug: Flutiform

First Posted Date: 2012-01-18

Last Posted Date: 2018-10-24

Lead Sponsor: Mundipharma Research Limited

Target Recruit Count: 498

Registration Number: NCT01511367

Locations: 🇭🇺
Illés és Ádám Egészségügyi Szolgáltató Bt., Kiskunhalas, Hungary
🇨🇿
Alergologie Skopkova s.r.o, Ostrava-Marianske Hory, Czechia
🇵🇱
Alergo-Med Specjalistyczna Przychodnia Lekarska Sp.z.o.o., Tarnow, Poland

and more 1 locations

A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab.

Phase 3

Terminated

Conditions: Indolent B-cell NHL

Interventions: Drug: Bendamustine IV
Other: Treatment of Physicians Choice

First Posted Date: 2011-02-03

Last Posted Date: 2018-09-04

Lead Sponsor: Mundipharma Research Limited

Target Recruit Count: 88

Registration Number: NCT01289223

Locations: 🇸🇰
Dr Ludmila Demitrovicova, Bratislava, Slovakia
🇦🇺
Royal Adelaide Hospital, Adelaide, Australia
🇦🇺
Princess Alexandra Hospital, Brisbane, Queensland, Australia

Prospective Study on the Use of Transdermal Analgesic Buprenorphine Patches for Chronic Pain in the UK

Completed

Conditions: Chronic Pain

First Posted Date: 2010-10-21

Last Posted Date: 2014-05-15

Lead Sponsor: Mundipharma Research Limited

Target Recruit Count: 750

Registration Number: NCT01225861

Locations: 🇬🇧
Western Infirmary, Terrent Institute, Glasgow, United Kingdom

Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Flutiform
Drug: Symbicort Turbohaler

First Posted Date: 2010-04-07

Last Posted Date: 2018-10-24

Lead Sponsor: Mundipharma Research Limited

Target Recruit Count: 261

Registration Number: NCT01099722

Locations: 🇭🇺
Csongrád Megyei Önkormányzat Mellkasi Betegségek Szakkórháza Tüdőgondozó Intézet, Szeged, Hungary

Study to Assess Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adults With Mild to Moderate Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Fluticasone propionate / Formoterol fumarate

First Posted Date: 2009-10-15

Last Posted Date: 2018-10-24

Lead Sponsor: Mundipharma Research Limited

Target Recruit Count: 46

Registration Number: NCT00995800

Locations: 🇩🇪
KLB, Lubeck, Germany

A Study to Characterize the Pharmacokinetics and Tolerability of Buprenorphine Patches in Children With Moderate to Severe Mouth Pain

Phase 1

Terminated

Conditions: Chemotherapy Induced Mucositis
Mouth Pain

Interventions: Drug: Buprenorphine

First Posted Date: 2009-07-28

Last Posted Date: 2018-10-24

Lead Sponsor: Mundipharma Research Limited

Target Recruit Count: 25

Registration Number: NCT00947466

Locations: 🇬🇧
Dr Howell, Liverpool, United Kingdom

Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis.

Phase 1

Completed

Conditions: Solid Tumour Neoplastic Meningitis
Brain Metastases

Interventions: Drug: Whole brain radiotherapy (WBRT) with concomitant Depocyte
Drug: Whole Brain Radio Therapy (WBRT) with sequential Depocyte

First Posted Date: 2009-03-03

Last Posted Date: 2014-02-24

Lead Sponsor: Mundipharma Research Limited

Target Recruit Count: 18

Registration Number: NCT00854867

Locations: 🇦🇹
Kaiser-Franz-Josef-Spital, Vienna, Austria
🇦🇹
University Internal Medicine Clinic III, Salzburg, Austria
🇦🇹
Klagenfurt Regional Hospital, Klagenfurt, Austria

and more 3 locations

Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.

Phase 1

Terminated

Conditions: Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia
B-cell Precursor Acute Lymphoblastic Leukaemia
T-cell Non-Hodgkin's Lymphoma

First Posted Date: 2008-08-27

Last Posted Date: 2012-10-24

Lead Sponsor: Mundipharma Research Limited

Target Recruit Count: 2

Registration Number: NCT00742495

Locations: 🇫🇷
Prof Gerard Michel, Marseilles, France
🇩🇪
Charite Universitymedicine, Berlin, Germany
🇮🇹
Dr Giovanna Gioriani, Pavia, Italy

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy